A new switch to help T cells fight cancer
A Novel Regulator of Antitumor Immunity and Immunotherapy
This work looks at whether a protein called NELF can help tumor-fighting CD8+ T cells work better for people with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11286794 on NIH RePORTER |
What this research studies
From a patient perspective, the team is studying how the protein NELF controls the behavior of CD8+ T cells inside tumors using lab-grown cells and animal models. They will compare T cells in the tumor microenvironment with those in nearby lymph nodes to see why T cells become exhausted when exposed to lots of tumor antigen. The researchers will separate NELF's actions in the cell nucleus versus the cytoplasm to learn how it affects gene activity and immune function. They will also test whether changing NELF activity can boost the effectiveness of T cell–based immunotherapies such as CAR‑T approaches in preclinical models.
Who could benefit from this research
Good fit: People with cancers that are treated with or might be candidates for T cell–based immunotherapies, especially those whose tumors show signs of CD8+ T cell exhaustion, would be the most relevant group.
Not a fit: Patients with cancers that do not rely on T cell responses or who are not candidates for immunotherapy are unlikely to gain direct benefit from this preclinical work.
Why it matters
Potential benefit: If successful, this could lead to new ways to reduce T cell exhaustion and make immunotherapies like CAR‑T and checkpoint blockers work better for cancer patients.
How similar studies have performed: Existing immunotherapies such as checkpoint inhibitors and CAR‑T cells have helped many patients, but targeting transcriptional regulators like NELF is a relatively new preclinical approach that has shown promise in laboratory studies but is not yet proven in people.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Li, Rong — George Washington University
- Study coordinator: Li, Rong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.